TP ICAP Midcap Initiates Coverage of Oncodesign Precision Medicine With a “Buy” Recommendation
December 12 2023 - 12:00PM
Business Wire
Regulatory News:
Oncodesign Precision Medicine (OPM) (ISIN : FR001400CM63 ;
Mnemonic : ALOPM) (Paris:ALOPM), a biopharmaceutical company
specializing in precision medicine for the treatment of resistant
and metastatic cancer, today announced that TP ICAP Midcap, a
brokerage firm and investment bank specializing in small and
mid-caps, has initiated coverage of its shares.
In its initiation study entitled “Identify the Effective
Therapeutic Route””, TP ICAP Midcap began covering the stock with a
“Buy” recommendation and valued the Company at €2.75 per
share.1
About Oncodesign Precision Medicine (OPM)
Oncodesign Precision Medicine (OPM), the result of the transfer
of Oncodesign's Biotech and AI activities, is a biopharmaceutical
company specializing in precision medicine to treat resistant and
metastatic cancers.
OPM's innovative technologies are (i) OncoSNIPER for the
selection of therapeutic targets using artificial intelligence;
(ii) Nanocyclix® for the design and selection of macrocyclic small
molecule kinase inhibitors and (iii) Promethe for the design and
selection of radiolabeled biological molecules for systemic
radiotherapy.
From these technologies, OPM has built a portfolio of
therapeutic products. A first drug candidate based on the
Nanocyclix® technology entered the clinical phase in 2022, in
partnership with SERVIER (which exercised its option for an
exclusive worldwide license on the program) to treat Parkinson's
disease. OPM-101 is OPM's second candidate to enter the clinic, in
the treatment of chronic immuno-inflammatory diseases. Finally, OPM
is also collaborating with Servier to discover new therapeutic
targets for the treatment of pancreatic adenocarcinoma based on its
OncoSNIPER technology. In addition, OPM is seeking a partner for
Florepizol, a radiotracer specific for the mutated EGFR target,
which has successfully completed Phase I. Finally, OPM has a
significant portfolio of early-stage projects with Nanocyclix® and
Promethe in oncology. With this portfolio of molecules and
diversified therapeutic targets, OPM's mission is to discover
effective therapies to treat resistant and advanced cancers. Based
in Dijon, at the heart of the university and hospital cluster, OPM
has 25 employees.
More info at: oncodesign.com
--------------
1 This information does not constitute an offer to sell or
subscribe, or the solicitation of an order to buy or subscribe,
securities in France, Europe, the United States or any other
country. The provision of a financial analysis production and
dissemination service has been agreed between Oncodesign Precision
Medicine and TP ICAP Midcap.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231212381936/en/
OPM Karine Lignel Deputy General Manager Tel: +33 (0)3 80
78 41 93 investisseurs@oncodesign.com
NewCap Investor Relations Mathilde Bohin / Alban Dufumier
Tel: +33 (0)1 44 71 94 95 oncodesign@newcap.eu
NewCap Media Relations Arthur Rouillé Tel: +33 (0)1 44 71
00 15 oncodesign@newcap.eu
Oncodesign Precision Med... (EU:ALOPM)
Historical Stock Chart
From Dec 2024 to Jan 2025
Oncodesign Precision Med... (EU:ALOPM)
Historical Stock Chart
From Jan 2024 to Jan 2025
